



One line pitch:

Artificial Pancreas service for Diabetes treatment. We will save lives, amputations, ocular and renal complications, and radically improve everyday life for the patients.

Market Analysis:

The Artificial Pancreas is aimed at diabetes patients that treat themselves with insulin every day, e.g. type 1 and a small portion of type 2, representing 300,000 patients in France and 2 million in Europe. This population has been increasing steadily at around 4% per year. The annual healthcare costs of a diabetes patient are quite high, and an artificial pancreas would significantly decrease this cost through lower incident rate and ongoing costs, even including the cost of the service itself. Combined with the huge impact an AP has on everyday life of a patient, who no longer has to measure his own doses constantly, we believe there is a very large effective market for an AP service, with potentially rapid adoption (for a medical device)

Business Proposition:

Diabeloop is the integrations of 5 things: an Insulin Pump, a glucose sensor, a controller (restricted smartphone where the algorithm, control software and interface resides), a remote server with alert algorithms and an interface for the medical team, and design of a patient support service for dedicated nurses. This service will significantly reduce hypoglycemic events and associated comas, increase glucose control and associated ocular, renal complications and amputations, and fundamentally improve everyday life of diabetes patients.

Competitive Advantage:

There are currently no Artificial Pancreas on the market, and we believe that Diabeloop will be the first to be approved. Diabeloop is unique in that it combines an academic background, direct diabetes care experience, industrialization expertise and a strong network with the medical regulatory authorities. The CERITD, Guillaume Charpentier and 10 university diabetes centers form an outstanding research and clinical team. The CEA brings the integration, algorithm and industrialization expertise. And the CERITD already treats a large number of patients, bringing both care and service expertise along with the authorities network. The differentiating factor in the AP market will be the ability to bring all these areas together, rather than just one specific area of expertise.

Investment Attractiveness:

Diabeloop will deliver a unique care service to diabetes patients, and aims to be the first approved AP service on the market. Diabeloop will significantly reduce deaths and complications while minimizing the everyday burden of diabetes for the patients. The underlying market is (unfortunately) large, with robust growth. Because of the large costs associated with treating diabetes patients and the savings brought by an AP service, we believe that Diabeloop will be reimbursed by the payers. There is significant interest from industry players as well (upstream and downstream included).

IP Situation:

Diabeloop currently owns no patents on this project. There will be a certain number of patents coming on specific areas. The key barrier to entry lies in the integration of devices, code and service, and the link to the clinical studies. This is not easy to protect via patents but still represents a formidable asset. There will be copyright protection on the code and algorithms as well for Diabeloop.



COMPANY PROFILE

- **Website:**
www.diabeloop.fr
- **Activity:** MedTech
- **Contact:**
HUNEKER Erik
erik@diabeloop.fr
- **Location:**
1, rue pierre fontaine
91058 evry
France
- **Founded in:** 01/01/2012
- **Employees:** 7
- **Management:**
Charpentier Guillaume
Président
- **Financial information (€):**
 - **Company stage:**
 - **Capital raised to date:**
 - **Monthly burn rate:**
 - **Capital seeking and date:**
12M€, Q1-Q2'16
- **Investors:**
CERITD, non-profit organization.
- **Referred by:**
Lyon Biopole